$JNCE

Jounce Therapeutics Inc

  • NASDAQ
  • Health Technology
  • Biotechnology
  • Manufacturing
  • Biological Product (except Diagnostic) Manufacturing

PRICE

$3.17 ▲4.967%

Last Close

VOLUME

107,491

DAY RANGE

2.92 - 3.17

52 WEEK

2.76 - 9.81

Join Discuss about JNCE with like-minded investors

profile
@viking #StockTraders.NET
recently

anyone have a position in $JNCE?

60 Replies 12 👍 12 🔥

DO
@Dominader #StockTraders.NET
recently

Ss JNCE 10.88

61 Replies 6 👍 13 🔥

profile
@Neptune5045 #StockTraders.NET
recently

$VVPR $JNCE $GOGO on watch for me

78 Replies 7 👍 8 🔥

profile
@TraderXx #StockTraders.NET
recently

and here goes $JNCE

103 Replies 15 👍 9 🔥

profile
@TraderXx #StockTraders.NET
recently

$JNCE 8.50's should be a pivotal area

91 Replies 12 👍 8 🔥

profile
@TraderXx #StockTraders.NET
recently

$JNCE volume looks promising

67 Replies 15 👍 9 🔥

profile
@TraderXx #StockTraders.NET
recently

still watching $JNCE, might come back later

51 Replies 6 👍 12 🔥

profile
@TraderXx #StockTraders.NET
recently

sold the rest $JNCE

123 Replies 13 👍 13 🔥

profile
@TraderXx #StockTraders.NET
recently

sold some $JNCE

81 Replies 6 👍 10 🔥

profile
@TraderXx #StockTraders.NET
recently

$JNCE wants to halt on the way up, I see it

131 Replies 15 👍 6 🔥

Key Metrics

Market Cap

163.81 M

Beta

1.25

Avg. Volume

346.81 K

Shares Outstanding

51.67 M

Yield

0%

Public Float

0

Next Earnings Date

2022-08-04

Next Dividend Date

Company Information

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce's highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce's internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounce's most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce's broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc.

CEO: Richard Murray

Website:

HQ: 780 Memorial Dr Cambridge, 02139-4613 Massachusetts

Related News